Medical Condition News

RSS

‘Sleeping sickness’ pandemic offers insight into Parkinson’s

A bizarre disease that caused sufferers to fall into a deep ‘sleep’ while still being aware of their surroundings can offer us insight into the nature of Parkinson’s disease.

21 Mar 2011

Bowel cancer incidence set to rise: Research

According to the latest research from the Cancer Council, the incidence of bowel cancer in Australia is set to rise to 21,000 cases a year in the next decade. The report shows that one in five cases are diagnosed at an advanced stage, due to a lack of screening. This research is being used to renew the Federal Government’s full funding and implementation of the national bowel cancer screening program. Funding for the program is due to expire at the end of June.

21 Mar 2011

Differences between therapeutic radiation therapy and exposure to excessive nuclear plant fallout radiation

"The Canadian Association of Radiation Oncology (http://www.caro-acro.ca) is the voice for specialists in Canada who treat patients' cancer with radiation. In that capacity," explains Dr. Matthew Parliament, president of CARO-ACRO, "we work with proven, controlled, targeted application of various forms of radiation therapy to treat and cure cancer."

21 Mar 2011

ViroPharma launches online community for teens and adults with hereditary angioedema

ViroPharma Incorporated today announced the launch of "HAE and Me," an online community that unites teens and adults with hereditary angioedema (HAE) through shared experiences to help them better manage their disease.

21 Mar 2011

ADDF awards ADispell 170,750 grant to develop drugs against Alzheimer's Disease

The Alzheimer's Drug Discovery Foundation (ADDF) announced that it has awarded a grant of $170,750 to ADispell Inc. to develop small molecule drugs designed to halt the progression of cognition loss that occurs with Alzheimer's Disease.

21 Mar 2011

Researcher reverses ageing process in bee's brain

Norwegian researcher Gro Amdam has succeeded in reversing the ageing process in the bee brain - findings which she believes may bring hope to people with dementia.

21 Mar 2011

Svelte Medical completes 6 month follow up in initial Acrobat angioplasty system clinical trial

Svelte™ Medical Systems, Inc. is pleased to announce that it has completed 6 month follow up in its initial clinical trial with the Svelte Acrobat angioplasty system.

21 Mar 2011

Study unravels molecular mechanism of biomolecule RNA that plays dynamic regulatory role in protein selection

If a big bunch of your brain cells suddenly went rogue and decided to become fat cells, it could cloud your decision-making capacity a bit. Fortunately, early in an organism's development, cells make firm and more-or-less permanent decisions about whether they will live their lives as, say, skin cells, brain cells or, well, fat cells.

21 Mar 2011

Sarsia Seed provides follow-up funding for APIM Therapeutics

APIM Therapeutics AS, an early-stage Norwegian therapeutic company, is pursuing a novel drug approach with the ability to potentiate the action of a wide range of chemotherapeutic drugs currently used to treat several types of cancer.

21 Mar 2011

SLEH treats irregular heartbeat with novel minimally invasive cold cryoballoon technology

A physician affiliated with Texas Heart® Institute (THI) at St. Luke's Episcopal Hospital (SLEH) is the first in Houston and among the first in the nation to treat patients for an irregular heartbeat with a new, minimally invasive cryoballoon technology that uses cold rather than heat to interrupt faulty electrical circuits in the heart.

21 Mar 2011

NasVax reports positive results from Phase 2a trial of oral immunotherapy for non-alcoholic steatohepatitis

NasVax announces the success of a Phase 2a clinical trial of a new oral immunotherapy for non-alcoholic steatohepatitis (NASH), an inflammatory disease associated with fatty liver disease and the metabolic syndrome.

21 Mar 2011

Innovative algorithm for AEDs distinguishes betweeen adult and child arrhythmias

Ventricular Fibrillation (VF) is a series of intense and disordered contractions of the ventricles (they are located in the lower part of the heart). In 40 % of respiratory arrests suffered outside a hospital, it was shown that the first cardiac rhythm corresponds to VF, and the only manner to combat it is with electric discharges provided by defibrillation. This

21 Mar 2011

Research outlines how cilia disease gene products regulate early cilium formation

An international collaboration jointly led by University College Dublin, University of Alabama and Simon Fraser University, British Columbia has outlined in the Journal of Cell Biology how cilia disease gene products regulate important aspects of early cilium formation and the integrity of the ciliary transport gate.

21 Mar 2011

Nektar initiates dosing in NKTR-181 Phase 1 clinical study for treatment of pain

Nektar Therapeutics today announced that the first subjects were dosed in a new Phase 1 clinical study to evaluate NKTR-181, the company's next-generation opioid analgesic candidate. NKTR-181 is being developed to effectively treat pain while addressing the abuse liability and serious CNS side effects associated with currently available opioid therapies.

21 Mar 2011

United Therapeutics completes enrollment in FREEDOM-C(2) UT-15C study in pulmonary arterial hypertension

United Therapeutics Corporation announced today that enrollment in its FREEDOM-C(2) registration trial was completed on March 18, 2011.

21 Mar 2011

First clinical use of GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface on lower profile delivery system

W. L. Gore & Associates (Gore) today reported the first clinical use in the U.S. of the GORE® VIABAHN® Endoprosthesis with Heparin Bioactive Surface on a lower profile delivery system. The GORE VIABAHN Device is designed to percutaneously treat Superficial Femoral Artery (SFA) and iliac peripheral artery disease by relining the native vessel.

21 Mar 2011

Shire announces FDA PDUFA date for FIRAZYR NDA in treatment of acute attacks of hereditary angioedema

Shire plc, the global specialty biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) date of August 25, 2011 for the review of the New Drug Application (NDA) for FIRAZYR(R) (icatibant) for the treatment of acute attacks (Types I and II) of hereditary angioedema (HAE). This 6 month review timeline is consistent with review as a Class II resubmission.

21 Mar 2011

Study on mandibular changes produced by skeletal anchorage assisted orthopedic traction

Today, during the 89th General Session & Exhibition of the International Association for Dental Research, held in conjunction with the 40th Annual Meeting of the American Association for Dental Research and the 35th Annual Meeting of the Canadian Association for Dental Research, lead researcher T. Nguyen will hold an oral presentation on a study titled "Mandibular Changes Produced by Skeletal Anchorage Assisted Orthopedic Traction."

21 Mar 2011

Physical ill-health reduces life expectancy of people with severe mental illness

Physical ill-health is rife among the severely mentally ill in Britain, according to new research published today by the University of East Anglia (UEA).

21 Mar 2011

XenoPort reports preliminary top-line results from arbaclofen placarbil Phase 2b clinical trial in GERD

XenoPort, Inc. announced today preliminary top-line results from a Phase 2b clinical trial of arbaclofen placarbil (also known as AP) as adjunctive therapy in patients with gastroesophageal reflux disease (GERD) who do not experience complete relief of GERD symptoms while being treated with proton pump inhibitors (PPI).

21 Mar 2011

Medical Condition News

‘Sleeping sickness’ pandemic offers insight into Parkinson’s

Bowel cancer incidence set to rise: Research

Differences between therapeutic radiation therapy and exposure to excessive nuclear plant fallout radiation

ViroPharma launches online community for teens and adults with hereditary angioedema

ADDF awards ADispell 170,750 grant to develop drugs against Alzheimer's Disease

Researcher reverses ageing process in bee's brain

Svelte Medical completes 6 month follow up in initial Acrobat angioplasty system clinical trial

Study unravels molecular mechanism of biomolecule RNA that plays dynamic regulatory role in protein selection

Sarsia Seed provides follow-up funding for APIM Therapeutics

SLEH treats irregular heartbeat with novel minimally invasive cold cryoballoon technology

NasVax reports positive results from Phase 2a trial of oral immunotherapy for non-alcoholic steatohepatitis

Innovative algorithm for AEDs distinguishes betweeen adult and child arrhythmias

Research outlines how cilia disease gene products regulate early cilium formation

Nektar initiates dosing in NKTR-181 Phase 1 clinical study for treatment of pain

United Therapeutics completes enrollment in FREEDOM-C(2) UT-15C study in pulmonary arterial hypertension

First clinical use of GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface on lower profile delivery system

Shire announces FDA PDUFA date for FIRAZYR NDA in treatment of acute attacks of hereditary angioedema

Study on mandibular changes produced by skeletal anchorage assisted orthopedic traction

Physical ill-health reduces life expectancy of people with severe mental illness

XenoPort reports preliminary top-line results from arbaclofen placarbil Phase 2b clinical trial in GERD

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News